Search clinical trials for: Raltegravir, tenofovir/emtricitabine

Total 1262 results

Fenway Community Health
Merck Sharp & Dohme LLC

Completed

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

HIV Infections

United States
First Affiliated Hospital Xi'an Jiaotong University

Unknown

Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection

Hepatitis B, Chronic

China
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients (VIH-2)

HIV-2 Infection

France
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

HIV

United States
National Institute of Allergy and Infectious Diseases...
Adult AIDS Clinical Trials Group

Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

HIV Infections

United States
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
St Stephens Aids Trust

Completed

Atripla to Raltegravir Switch Study for CNS Toxicity (SSAT036)

HIV Infection

United Kingdom
University of California, San Francisco
Merck Sharp & Dohme LLC; Gilead Sciences; California HIV/AIDS Research Program

Completed

HIV Persistence and Viral Reservoirs

HIV Infections | HIV

United States
Andrew Carr
Merck Sharp & Dohme LLC

Completed

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

HIV Infections | HIV Prevention

Australia
Catholic University of the Sacred Heart

Completed

Raltegravir Switch for Toxicity or Adverse Events (RaSTA)

HIV Infections | HIV/AIDS | Antiretroviral Therapy

Italy
University of North Carolina, Chapel Hill

Completed

A Key Link for Transmission Prevention (MP3)

HIV

Malawi
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
Abbott
Merck Sharp & Dohme LLC

Completed

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) (PROGRESS)

Human Immunodeficiency Virus Infection

United States, Canada, France, Italy, Poland, Puerto Rico, Spain
Hospital Clinic of Barcelona

Completed

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (RAL-PEP)

HIV Infection

Spain
St Vincent's Hospital, Sydney
Merck Sharp & Dohme LLC

Completed

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART. (ROaR+)

Cardiovascular Disease | HIV

Australia
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

HIV Infection | Hepatitis C

United States
Germans Trias i Pujol Hospital

Completed

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

HIV Infections

Spain
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC

Completed

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients (RAN)

HIV Infections

United States
University of Alberta
Merck Sharp & Dohme LLC

Completed

Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis

Canada
Community Research Initiative of New England
Merck Sharp & Dohme LLC

Withdrawn

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

HIV Infections | Acquired Immune Deficiency Syndrome
George Washington University

Terminated

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

HIV Infections

United States
Margaret A. Fischl, M.D.

Completed

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects (HIV)

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) (onceMRK)

HIV Infection
Eastern Virginia Medical School
Gilead Sciences; United States Agency for International Development (USAID); FHI... and other collaborators

Active, not recruiting

Project Engage: Oral PrEP Acceptability

Adherence, Medication | Acceptability of Health Care

South Africa, Zimbabwe
Community Research Initiative of New England
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. (BATAR)

HIV

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

HIV Infection

United States
Gilead Sciences

Completed

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

HIV Infections

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
Indiana University
Merck Sharp & Dohme LLC

Completed

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

HIV

United States
AIDS Clinical Trials Group
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases... and other collaborators

Completed

Comparative Study of Three NNRTI-Sparing HAART Regimens

HIV Infection

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

HIV Infections

Zimbabwe, Uganda
University Health Network, Toronto
Gilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... and other collaborators

Completed

Bone Health in Aging HIV Infected Women (BEING)

Menopause | HIV | Osteoporosis

Canada, Italy
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

HIV Infections

South Africa, Uganda, Zimbabwe
University of California, San Diego
Gilead Sciences; University at Buffalo

Completed

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

HIV

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

HIV Infections

United States, Puerto Rico
Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
Valley AIDS Council
Gilead Sciences

Not yet recruiting

Advanced HIV: Outcomes for Rapid ART (AHORA)

HIV-1-infection
University of Nebraska
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE (BASE)

HIV-1-infection

United States
Fenway Community Health

Completed

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

HIV Prevention

United States
Dallas VA Medical Center
Merck Sharp & Dohme LLC; Tibotec Pharmaceutical Limited

Completed

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (RADAR)

HIV Infections

United States
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
University of California, San Diego

Active, not recruiting

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS)

Hiv | Hormone Therapy

United States
Imperial College London

Completed

The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age

HIV

United Kingdom
National Taiwan University Hospital
Mackay Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital and other collaborators

Unknown

Same-day Antiretroviral Therapy With BIC/F/TAF

HIV Infections

Taiwan
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
Janssen Sciences Ireland UC

Completed

Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination

Healthy

Belgium
Merck Sharp & Dohme LLC

Active, not recruiting

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

Prophylaxis | Human Immunodeficiency Virus Type 1 | HIV-I

United States, South Africa, Uganda
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal

Search clinical trials for: Raltegravir, tenofovir/emtricitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations